XML 62 R51.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Revenue recognition - Narrative (Details) | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
Oct. 31, 2017 USD ($) | Nov. 30, 2014 USD ($) | Jan. 31, 2014 USD ($) | Nov. 30, 2011 USD ($) compound | Mar. 31, 2018 USD ($) segment deliverable | Mar. 31, 2017 USD ($) | Dec. 31, 2017 USD ($) deliverable
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |
Number of operating segments | segment |  |  |  |  | 1 |  |
Net product revenue |  |  |  |  | $ 55,981,000 | $ 26,442,000 |
Contract with customer, liability |  |  |  |  |  |  | $ 11,891,000
Upfront cash payment |  |  |  |  | 1,346,000 |  |
Licensing And Collaboration Agreement |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |
Upfront cash payment |  |  |  | $ 30,000,000 |  |  |
Revenue recognition, milestone method, revenue recognized | $ 20,000,000 | $ 10,000,000 | $ 7,500,000 |  |  |  |
Revenues |  |  |  |  | 100,000 | 100,000 |
Licensing And Collaboration Agreement | Research And Development Event Milestones |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |
Revenue recognition, milestone, potential achievements |  |  |  |  | 135,000,000 |  |
Licensing And Collaboration Agreement | Sales Milestones |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |
Revenue recognition, milestone, potential achievements |  |  |  |  | 325,000,000 |  |
Discovery Agreements |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |
Revenues |  |  |  |  | 0 | 0 |
Early Stage Collaborations |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |
Revenues |  |  |  |  | 0 | $ 0 |
Early Stage Collaborations | Research And Development Event Milestones |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |
Revenue recognition, milestone, potential achievements |  |  |  |  | 143,000,000 |  |
Early Stage Collaborations | Sales Milestones |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |
Revenue recognition, milestone, potential achievements |  |  |  |  | 252,000,000 |  |
United States | Emflaza |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |
Net product revenue |  |  |  |  | 19,200,000 |  |
Non-US | Translarna |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |
Net product revenue |  |  |  |  | $ 36,800,000 |  |
Collaborative Arrangement | Roche And Sma Foundation |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |
Number of compounds in preclinical development | compound |  |  |  | 3 |  |  |
Number of significant deliverables | deliverable |  |  |  |  |  |  | 2
Collaboration And Discovery Agreements |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |
Number of significant deliverables | deliverable |  |  |  |  | 2 |  |
Minimum | Collaboration And Discovery Agreements |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |
Collaborative arrangements research period for applying discovery technology |  |  |  |  | 3 years |  |
Maximum | Collaboration And Discovery Agreements |  |  |  |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |  |  |  |
Collaborative arrangements research period for applying discovery technology |  |  |  |  | 4 years |  |

X
- Definition Represents the number of compounds included in preclinical development. + References No definition available. + Details
Name: | ptct_CollaborativeArrangementsNumberOfCompoundsInPreclinicalDevelopment
Namespace Prefix: | ptct_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of significant deliverables under a contractual agreement. + References No definition available. + Details
Name: | ptct_CollaborativeArrangementsNumberOfSignificantDeliverables
Namespace Prefix: | ptct_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the research period for applying discovery technology. + References No definition available. + Details
Name: | ptct_CollaborativeArrangementsResearchPeriodForApplyingDiscoveryTechnology
Namespace Prefix: | ptct_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contract with Customer, Liability, Increase from Cash Receipts + References No definition available. + Details
Name: | ptct_ContractWithCustomerLiabilityIncreaseFromCashReceipts
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of revenue earned from product sales during the reporting period. + References No definition available. + Details
Name: | ptct_NetProductSales
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue Recognition, Milestone, Potential Achievements + References No definition available. + Details
Name: | ptct_RevenueRecognitionMilestonePotentialAchievements
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + References No definition available. + Details
Name: | us-gaap_NumberOfOperatingSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ProductOrServiceAxis=ptct_LicensingAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ptct_MilestoneAxis=ptct_ResearchAndDevelopmentEventMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ptct_MilestoneAxis=ptct_SalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=ptct_DiscoveryAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=ptct_EarlyStageCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=ptct_EmflazaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=ptct_TranslarnaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=ptct_RocheAndSmaFoundationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptct_CollaborationAndDiscoveryAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |